{"id":390321,"date":"2019-11-28T00:00:00","date_gmt":"2019-11-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0001-2019-biopharma-asthma-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-03-31T10:46:02","modified_gmt":"2026-03-31T10:46:02","slug":"dlsfim0001-2019-biopharma-asthma-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0001-2019-biopharma-asthma-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Asthma | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline\u2019s Advair \/ Seretide, AstraZeneca\u2019s Symbicort, Boehringer Ingelheim\u2019s Spiriva), oral drugs (e.g., montelukast), and biologics (e.g., Roche \/ Novartis\u2019s Xolair, GlaxoSmithKline\u2019s Nucala). However, market dynamics are evolving as branded generic and generic alternatives to inhaled blockbuster agents continue to launch and new biologics targeting niche populations within the severe asthma segment are approved. These events have increased\u2014and will continue to increase\u2014competition in this lucrative market. With the impending entry of an additional biological therapy, the launch of branded generic and generic inhaled drugs in new markets, and the potential launch of\u00a0<abbr title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>\/<abbr title=\"inhaled corticosteroid\">ICS<\/abbr>\u00a0combination agents, the asthma market is poised to experience change over the next decade.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What are\u00a0<abbr title=\"key opinion leader\">KOL<\/abbr>s\u2019 insights on current inhaled branded, branded generic, and generic treatment options? What is \/ will be the market impact of branded generic and generic inhaled therapies?<\/li>\n<li>What are\u00a0<abbr title=\"key opinion leader\">KOL<\/abbr>s\u2019 perceptions of the currently marketed asthma biologics (Xolair, Nucala, Teva\u2019s Cinqair \/ Cinqaero, AstraZeneca\u2019s Fasenra)? Where in the treatment algorithm do physicians fit these drugs? What drives physicians\u2019 choice of a biologic in severe, refractory asthma patients?<\/li>\n<li>How will the market evolve over the next ten years given the launch of additional inhaled, oral, and biological products? Will the entry of triple\u00a0<abbr title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>\/<abbr title=\"inhaled corticosteroid\">ICS<\/abbr>\u00a0combination agents and SABA\/ICS combination agents have a substantial effect on the sales and patient share of currently marketed asthma therapies? Where do physicians see these combination therapies fitting in the treatment algorithm?<\/li>\n<\/ul>\n<p><strong>Scope:<\/strong><\/p>\n<p><b>Markets covered:<\/b>\u00a0United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><b>Primary research:<\/b>\u00a039 country-specific interviews with thought leaders.<\/p>\n<p><b>Epidemiology:<\/b>\u00a0Number of diagnosed and drug-treated prevalent cases of asthma; number of diagnosed and drug-treated prevalent cases of intermittent \/ mild persistent and moderate \/ severe persistent asthma.<\/p>\n<p><b>Emerging therapies:\u00a0<\/b>Preregistered: 2 drug; Phase III: 8 drugs; Phase II: 11 drugs; coverage of 1 select Phase I product.<\/p>\n","protected":false},"template":"","class_list":["post-390321","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-asthma","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390321\/revisions"}],"predecessor-version":[{"id":393446,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390321\/revisions\/393446"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}